RecruitingPhase 3NCT05812807
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Sponsor: Alliance for Clinical Trials in Oncology
Baton Rouge, LA · +825 more sites